Aromatase, estrone sulfatase, and 17β-hydroxysteroid dehydrogenase: Structure-function studies and inhibitor development

Molecular and Cellular Endocrinology

Volumn 340, Issue 2, 2011, Pages 120-126

  Hong, Yanyan ^a   Chen, Shiuan ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

17 Hydroxysteroid dehydrogenase; Aromatase; Breast cancer; Crystal structure; Estrone sulfatase; Inhibitor

Indexed keywords

ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; E2B; EM 1745; ENZYME INHIBITOR; ESTERASE INHIBITOR; ESTROGEN; ESTRONE 3 SULFAMATE; ESTRONE SULFATASE; EXEMESTANE; HYDROXYSTEROID DEHYDROGENASE; IROSUSTAT; LETROZOLE; OXIDOREDUCTASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE; STERYL SULFATASE; TESTOSTERONE; UNCLASSIFIED DRUG;

BREAST CANCER; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; ESTROGEN SYNTHESIS; HUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; STRUCTURE ACTIVITY RELATION;

17-HYDROXYSTEROID DEHYDROGENASES; ANIMALS; AROMATASE; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFATASES;

EID: 79960214254     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2010.09.012     Document Type: Review

References (84)

1. Adams L.S., Chen S. Phytochemicals for breast cancer prevention by targeting aromatase. Front. Biosci. 2009, 14:3846-3863.
2. Aka J.A., Mazumdar M., Chen C.Q., Poirier D., Lin S.X. 17Beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production. Mol. Endocrinol. 2010, 24(4):832-845.
3. Akhtar M., Calder M.R., Corina D.L., Wright J.N. Mechanistic studies on C-19 demethylation in oestrogen biosynthesis. Biochem. J. 1982, 201(3):569-580.
4. Auvray P., Nativelle C., Bureau R., Dallemagne P., Seralini G.E., Sourdaine P. Study of substrate specificity of human aromatase by site directed mutagenesis. Eur. J. Biochem. 2002, 269(5):1393-1405.
5. Azzi A., Rehse P.H., Zhu D.W., Campbell R.L., Labrie F., Lin S.X. Crystal structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase complexed with 17 beta-estradiol. Nat. Struct. Biol. 1996, 3(8):665-668.
6. Bajetta E., Zilembo N., Bichisao E., Martinetti A., Buzzoni R., Pozzi P., Bidoli P., Ferrari L., Celio L. Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors. Ann. Oncol. 2000, 11(8):1017-1022.
7. Bond C.S., Clements P.R., Ashby S.J., Collyer C.A., Harrop S.J., Hopwood J.J., Guss J.M. Structure of a human lysosomal sulfatase. Structure 1997, 5(2):277-289.
8. Breton R., Housset D., Mazza C., Fontecilla-Camps J.C. The structure of a complex of human 17beta-hydroxysteroid dehydrogenase with estradiol and NADP+ identifies two principal targets for the design of inhibitors. Structure 1996, 4(8):905-915.
9. Brodie H.J., Kripalani K.J., Possanza G. Studies on the mechanism of estrogen biosynthesis. VI. The stereochemistry of hydrogen elimination at C-2 during aromatization. J. Am. Chem. Soc. 1969, 91(5):1241-1242.
10. Brozic P., Lanisnik Risner T., Gobec S. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Curr. Med. Chem. 2008, 15(2):137-150.
11. Brueggemeier R.W., Gu X., Mobley J.A., Joomprabutra S., Bhat A.S., Whetstone J.L. Effects of phytoestrogens and synthetic combinatorial libraries on aromatase, estrogen biosynthesis, and metabolism. Ann. N.Y. Acad. Sci. 2001, 948:51-66.
12. Choate J.V., Resko J.A. Paradoxical effect of an aromatase inhibitor, CGS 20267, on aromatase activity in guinea pig brain. J. Steroid Biochem. Mol. Biol. 1996, 58(4):411-415.
13. Day J.M., Foster P.A., Tutill H.J., Parsons M.F., Newman S.P., Chander S.K., Allan G.M., Lawrence H.R., Vicker N., Potter B.V., et al. 17Beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int. J. Cancer 2008, 122(9):1931-1940.
14. Day J.M., Tutill H.J., Newman S.P., Purohit A., Lawrence H.R., Vicker N., Potter B.V., Reed M.J. 17Beta-hydroxysteroid dehydrogenase Type 1 and Type 2: association between mRNA expression and activity in cell lines. Mol. Cell. Endocrinol. 2006, 248(1-2):246-249.
15. Dierks T., Schmidt B., von Figura K. Conversion of cysteine to formylglycine: a protein modification in the endoplasmic reticulum. Proc. Natl. Acad. Sci. U.S.A. 1997, 94(22):11963-11968.
16. Dunbier A.K., Anderson H., Ghazoui Z., Folkerd E.J., A'Hern R., Crowder R.J., Hoog J., Smith I.E., Osin P., Nerurkar A., et al. Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. J. Clin. Oncol. 2010, 28(7):1161-1167.
17. Edery M., Goussard J., Dehennin L., Scholler R., Reiffsteck J., Drosdowsky M.A. Endogenous oestradiol-17beta concentration in breast tumours determined by mass fragmentography and by radioimmunoassay: relationship to receptor content. Eur. J. Cancer 1981, 17(1):115-120.
18. Evans T.R., Di Salle E., Ornati G., Lassus M., Benedetti M.S., Pianezzola E., Coombes R.C. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res. 1992, 52(21):5933-5939.
19. Favia A.D., Cavalli A., Masetti M., Carotti A., Recanatini M. Three-dimensional model of the human aromatase enzyme and density functional parameterization of the iron-containing protoporphyrin IX for a molecular dynamics study of heme-cysteinato cytochromes. Proteins 2006, 62(4):1074-1087.
20. Foster P.A., Woo L.W., Potter B.V., Reed M.J., Purohit A. The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer. Endocrinology 2008, 149(8):4035-4042.
21. Gangloff A., Shi R., Nahoum V., Lin S.X. Pseudo-symmetry of C19 steroids, alternative binding orientations, and multispecificity in human estrogenic 17beta-hydroxysteroid dehydrogenase. FASEB J. 2003, 17(2):274-276.
22. Ghosh D., Griswold J., Erman M., Pangborn W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 2009, 457(7226):219-223.
23. Golob T., Liebl R., von Angerer E. Sulfamoyloxy-substituted 2-phenylindoles: antiestrogen-based inhibitors of the steroid sulfatase in human breast cancer cells. Bioorg. Med. Chem. 2002, 10(12):3941-3953.
24. Graham-Lorence S., Amarneh B., White R.E., Peterson J.A., Simpson E.R. A three-dimensional model of aromatase cytochrome P450. Protein Sci. 1995, 4(6):1065-1080.
25. Gunnarsson C., Olsson B.M., Stal O. Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Res. 2001, 61(23):8448-8451.
26. Hackett J.C., Brueggemeier R.W., Hadad C.M. The final catalytic step of cytochrome p450 aromatase: a density functional theory study. J. Am. Chem. Soc. 2005, 127(14):5224-5237.
27. Hahn E.F., Fishman J. Immunological probe of estrogen biosynthesis. Evidence for the 2 beta-hydroxylative pathway in aromatization of androgens. J. Biol. Chem. 1984, 259(3):1689-1694.
28. Haynes B.P., Straume A.H., Geisler J., A'Hern R., Helle H., Smith I.E., Lonning P.E., Dowsett M. Intratumoral estrogen disposition in breast cancer. Clin. Cancer Res. 2010, 16(6):1790-1801.
29. Hernandez-Guzman F.G., Higashiyama T., Pangborn W., Osawa Y., Ghosh D. Structure of human estrone sulfatase suggests functional roles of membrane association. J. Biol. Chem. 2003, 278(25):22989-22997.
30. Hong Y., Chen S. Aromatase inhibitors: structural features and biochemical characterization. Ann. N.Y. Acad. Sci. 2006, 1089:237-251.
31. Hong Y., Cho M., Yuan Y.C., Chen S. Molecular basis for the interaction of four different classes of substrates and inhibitors with human aromatase. Biochem. Pharmacol. 2008, 75(5):1161-1169.
32. Hong Y., Li H., Ye J., Miki Y., Yuan Y.C., Sasano H., Evans D.B., Chen S. Epitope characterization of an aromatase monoclonal antibody suitable for the assessment of intratumoral aromatase activity. PloS One 2009, 4(11):e8050.
33. Hong Y., Li H., Yuan Y.C., Chen S. Molecular characterization of aromatase. Ann. N.Y. Acad. Sci. 2009, 1155:112-120.
34. Hong Y., Yu B., Sherman M., Yuan Y.C., Zhou D., Chen S. Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. Mol. Endocrinol. 2007, 21(2):401-414.
35. Howarth N.M., Purohit A., Reed M.J., Potter B.V. Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem. 1994, 37(2):219-221.
36. Kadohama N., Zhou D., Chen S., Osawa Y. Catalytic efficiency of expressed aromatase following site-directed mutagenesis. Biochim. Biophys. Acta 1993, 1163(2):195-200.
37. Kagawa N., Hori H., Waterman M.R., Yoshioka S. Characterization of stable human aromatase expressed in E. coli. Steroids 2004, 69(4):235-243.
38. Kao Y.C., Cam L.L., Laughton C.A., Zhou D., Chen S. Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study. Cancer Res. 1996, 56(15):3451-3460.
39. Kao Y.C., Korzekwa K.R., Laughton C.A., Chen S. Evaluation of the mechanism of aromatase cytochrome P450. A site-directed mutagenesis study. Eur. J. Biochem. 2001, 268(2):243-251.
40. Kao Y.C., Zhou C., Sherman M., Laughton C.A., Chen S. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: a site-directed mutagenesis study. Environ. Health Perspect. 1998, 106(2):85-92.
41. Labrie F., Luu-The V., Lin S.X., Simard J., Labrie C., El-Alfy M., Pelletier G., Belanger A. Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol. 2000, 25(1):1-16.
42. Laplante Y., Cadot C., Fournier M.A., Poirier D. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone. Bioorg. Med. Chem. 2008, 16(4):1849-1860.
43. Laughton C.A., Zvelebil M.J., Neidle S. A detailed molecular model for human aromatase. J. Steroid Biochem. Mol. Biol. 1993, 44(4-6):399-407.
44. Lin S.X., Han Q., Azzi A., Zhu D., Gangloff A., Campbell R.L. 3D-structure of human estrogenic 17beta-HSD1: binding with various steroids. J. Steroid Biochem. Mol. Biol. 2000, 73(3-4):183.
45. Lin S.X., Zhu D.W., Azzi A., Campbell R.L., Breton R., Labrie F., Ghosh D., Pletnev V., Duax W.L., Pangborn W. Studies on the three-dimensional structure of estrogenic 17 beta-hydroxysteroid dehydrogenase. J. Endocrinol. 1996, 150(Suppl.):S13-20.
46. Lipton A., Demers L.M., Harvey H.A., Kambic K.B., Grossberg H., Brady C., Adlercruetz H., Trunet P.F., Santen R.J. Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 1995, 75(8):2132-2138.
47. Lonning P.E., Helle H., Duong N.K., Ekse D., Aas T., Geisler J. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J. Steroid Biochem. Mol. Biol. 2009, 117(1-3):31-41.
48. Mazumdar M., Fournier D., Zhu D.W., Cadot C., Poirier D., Lin S.X. Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy. Biochem. J. 2009, 424(3):357-366.
49. Millington D.S. Determination of hormonal steroid concentrations in biological extracts by high resolution mass fragmentography. J. Steroid Biochem. 1975, 6(3-4):239-245.
50. Miyairi S., Fishman J. Radiometric analysis of oxidative reactions in aromatization by placental microsomes. Presence of differential isotope effects. J. Biol. Chem. 1985, 260(1):320-325.
51. Miyoshi Y., Ando A., Shiba E., Taguchi T., Tamaki Y., Noguchi S. Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int. J. Cancer 2001, 94(5):685-689.
52. Morand P., Williamson D.G., Layne D.S., Lompa-Krzymien L., Salvador J. Conversion of an androgen epoxide into 17beta-estradiol by human placental microsomes. Biochemistry 1975, 14(3):635-638.
53. Numazawa M., Midzuhashi K., Nagaoka M. Metabolic aspects of the 1 beta-proton and the 19-methyl group of androst-4-ene-3,6,17-trione during aromatization by placental microsomes and inactivation of aromatase. Biochem. Pharmacol. 1994, 47(4):717-726.
54. Numazawa M., Tominaga T., Watari Y., Tada Y. Inhibition of estrone sulfatase by aromatase inhibitor-based estrogen 3-sulfamates. Steroids 2006, 71(5):371-379.
55. Pasqualini J.R. The selective estrogen enzyme modulators in breast cancer: a review. Biochim. Biophys. Acta 2004, 1654(2):123-143.
56. Pasqualini J.R., Chetrite G., Blacker C., Feinstein M.C., Delalonde L., Talbi M., Maloche C. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab. 1996, 81(4):1460-1464.
57. Persson B., Kallberg Y., Oppermann U., Jornvall H. Coenzyme-based functional assignments of short-chain dehydrogenases/reductases (SDRs). Chem. Biol. Interact. 2003, 143-144:271-278.
58. Plourde P.V., Dyroff M., Dowsett M., Demers L., Yates R., Webster A. ARIMIDEX: a new oral, once-a-day aromatase inhibitor. J. Steroid Biochem. Mol. Biol. 1995, 53(1-6):175-179.
59. Poirier D. Inhibitors of 17 beta-hydroxysteroid dehydrogenases. Curr. Med. Chem. 2003, 10(6):453-477.
60. Poirier D., Boivin R.P., Tremblay M.R., Berube M., Qiu W., Lin S.X. Estradiol-adenosine hybrid compounds designed to inhibit type 1 17beta-hydroxysteroid dehydrogenase. J. Med. Chem. 2005, 48(26):8134-8147.
61. Poutanen M., Isomaa V., Peltoketo H., Vihko R. Role of 17 beta-hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis. J. Steroid Biochem. Mol. Biol. 1995, 55(5-6):525-532.
62. Puranen T., Poutanen M., Ghosh D., Vihko R., Vihko P. Origin of substrate specificity of human and rat 17beta-hydroxysteroid dehydrogenase type 1, using chimeric enzymes and site-directed substitutions. Endocrinology 1997, 138(8):3532-3539.
63. Purohit A., Williams G.J., Howarth N.M., Potter B.V., Reed M.J. Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-O-sulfamate. Biochemistry 1995, 34(36):11508-11514.
64. Qiu W., Campbell R.L., Gangloff A., Dupuis P., Boivin R.P., Tremblay M.R., Poirier D., Lin S.X. A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity. FASEB J. 2002, 16(13):1829-1831.
65. Qiu W., Zhou M., Mazumdar M., Azzi A., Ghanmi D., Luu-The V., Labrie F., Lin S.X. Structure-based inhibitor design for an enzyme that binds different steroids: a potent inhibitor for human type 5 17beta-hydroxysteroid dehydrogenase. J. Biol. Chem. 2007, 282(11):8368-8379.
66. Sasano H., Suzuki T., Miki Y., Moriya T. Intracrinology of estrogens and androgens in breast carcinoma. J. Steroid Biochem. Mol. Biol. 2008, 108(3-5):181-185.
67. Sasano H., Suzuki T., Nakata T., Moriya T. New development in intracrinology of breast carcinoma. Breast Cancer (Tokyo, Japan) 2006, 13(2):129-136.
68. Sawicki M.W., Erman M., Puranen T., Vihko P., Ghosh D. Structure of the ternary complex of human 17beta-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+. Proc. Natl. Acad. Sci. U.S.A. 1999, 96(3):840-845.
69. Schmidt B., Selmer T., Ingendoh A., von Figura K. A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency. Cell 1995, 82(2):271-278.
70. Shi R., Lin S.X. Cofactor hydrogen bonding onto the protein main chain is conserved in the short chain dehydrogenase/reductase family and contributes to nicotinamide orientation. J. Biol. Chem. 2004, 279(16):16778-16785.
71. Smith I.E., Dowsett M. Aromatase inhibitors in breast cancer. N. Engl. J. Med. 2003, 348(24):2431-2442.
72. Stanway S.J., Delavault P., Purohit A., Woo L.W., Thurieau C., Potter B.V., Reed M.J. Steroid sulfatase: a new target for the endocrine therapy of breast cancer. Oncologist 2007, 12(4):370-374.
73. Tseng L., Mazella J., Lee L.Y., Stone M.L. Estrogen sulfatase and estrogen sulfotransferase in human primary mammary carcinoma. J. Steroid Biochem. 1983, 19(4):1413-1417.
74. van Landeghem A.A., Poortman J., Nabuurs M., Thijssen J.H. Endogenous concentration and subcellular distribution of androgens in normal and malignant human breast tissue. Cancer Res. 1985, 45(6):2907-2912.
75. Vermeulen A., Deslypere J.P., Paridaens R. Steroid dynamics in the normal and carcinomatous mammary gland. J. Steroid Biochem. 1986, 25(5B):799-802.
76. Vihko P., Harkonen P., Soronen P., Torn S., Herrala A., Kurkela R., Pulkka A., Oduwole O., Isomaa V. 17 beta-hydroxysteroid dehydrogenases-their role in pathophysiology. Mol. Cell. Endocrinol. 2004, 215(1-2):83-88.
77. Vihko P., Herrala A., Harkonen P., Isomaa V., Kaija H., Kurkela R., Pulkka A. Control of cell proliferation by steroids: the role of 17HSDs. Mol. Cell. Endocrinol. 2006, 248(1-2):141-148.
78. Vihko R., Apter D. Endogenous steroids in the pathophysiology of breast cancer. Crit. Rev. Oncol. Hematol. 1989, 9(1):1-16.
79. Woo L.W., Bubert C., Sutcliffe O.B., Smith A., Chander S.K., Mahon M.F., Purohit A., Reed M.J., Potter B.V. Dual aromatase-steroid sulfatase inhibitors. J. Med. Chem. 2007, 50(15):3540-3560.
80. Woo L.W., Fischer D.S., Sharland C.M., Trusselle M., Foster P.A., Chander S.K., Di Fiore A., Supuran C.T., De Simone G., Purohit A., et al. Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography. Mol. Cancer Ther. 2008, 7(8):2435-2444.
81. Woo L.W., Jackson T., Putey A., Cozier G., Leonard P., Acharya K.R., Chander S.K., Purohit A., Reed M.J., Potter B.V. Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J. Med. Chem. 2010, 53(5):2155-2170.
82. Woo L.W., Sutcliffe O.B., Bubert C., Grasso A., Chander S.K., Purohit A., Reed M.J., Potter B.V. First dual aromatase-steroid sulfatase inhibitors. J. Med. Chem. 2003, 46(15):3193-3196.
83. Yoshida N., Osawa Y. Purification of human placental aromatase cytochrome P-450 with monoclonal antibody and its characterization. Biochemistry 1991, 30(12):3003-3010.
84. Zhu D.W., Lee X., Labrie F., Lin S.X. Crystal growth of human estrogenic 17beta-hydroxysteroid dehydrogenase. Acta Crystallogr. 1994, 50(Pt 4):550-555.